Can DHEA sulfate be converted in peripheral tissues into testosterone and estrogens?

Dehydroepiandrosterone sulfate (DHEA-S) serves as the primary circulating adrenal precursor reservoir for peripheral tissue sex steroid synthesis. Because it is water-soluble, DHEA-S relies on carrier-mediated transport to enter peripheral target tissues where it is converted locally into active androgens and estrogens.

Mechanistic pathways of peripheral conversion

• Intracrine transformation: Upon entering peripheral tissues—such as adipose, skin, and skeletal muscle—DHEA-S is desulfated by the gatekeeper enzyme steroid sulfatase (STS) into unconjugated DHEA.
• Enzymatic cascade: Free DHEA is converted to androstenedione by 3β-hydroxysteroid dehydrogenase (3β-HSD), and subsequently to active testosterone by 17β-HSD isoforms (including AKR1C3). Aromatase (CYP19A1) can further convert these androgenic intermediates into estrone and estradiol, allowing tissues to autonomously modulate their local hormonal microenvironments.

Underpinnings of hormonal discordance

• Enzymatic inefficiency: Clinical discordance between robust circulating DHEA-S and low tissue-available testosterone often indicates impaired local enzymatic conversion, specifically within the STS, 3β-HSD, or 17β-HSD pathways.
• SHBG regulation: Sex hormone-binding globulin (SHBG) strongly modulates the bioavailable testosterone pool. Elevated SHBG levels restrict the free testosterone fraction, creating a clinical picture of low tissue-available androgen despite normal adrenal precursor output. Conversely, metabolic factors like insulin resistance suppress hepatic SHBG, altering this equilibrium.

Bottom line

• A mismatch between intact circulating DHEA-S and low tissue-available testosterone represents a functional marker of downstream limitations—such as inefficient intracrine enzyme conversion or elevated SHBG binding—rather than a primary failure of upstream adrenal precursor production.